Resistance to Molecular Therapies for Hepatocellular Carcinoma [electronic resource] / / edited by Augusto Villanueva.. — 1st ed. 2017.. — XIII, 147 p. 16 illus. in color. : online resource. — (Resistance to Targeted Anti-Cancer Therapeutics,) 13 2196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics, 13 .
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma -- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma -- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance -- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance -- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma -- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma -- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma -- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.
Available to subscribing member institutions only. Доступно лише організаціям членам підписки.
Анотація: This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.